MBP and MAP2K1

Data Source:
BioGRID (enzymatic study)

		MBP	MAP2K1
Description		myelin basic protein	mitogen-activated protein kinase kinase 1
Image
GO Annotations	Cellular Component	Nucleus Plasma Membrane Cell Surface Protein-containing Complex Internode Region Of Axon Neuronal Cell Body Myelin Sheath Compact Myelin Synapse Cell Periphery	Nucleus Mitochondrion Early Endosome Late Endosome Endoplasmic Reticulum Golgi Apparatus Microtubule Organizing Center Cytosol Plasma Membrane Focal Adhesion
	Molecular Function	Protease Binding Protein Binding Calmodulin Binding Structural Constituent Of Myelin Sheath	Protein Kinase Activity Protein Serine/threonine Kinase Activity MAP Kinase Kinase Activity Protein Serine/threonine/tyrosine Kinase Activity Protein Tyrosine Kinase Activity MAP-kinase Scaffold Activity Protein Binding ATP Binding Protein C-terminus Binding Protein Serine/threonine Kinase Activator Activity Protein N-terminus Binding Scaffold Protein Binding
	Biological Process	MAPK Cascade Immune Response Chemical Synaptic Transmission Central Nervous System Development Sensory Perception Of Sound Axon Ensheathment Response To Toxic Substance Substantia Nigra Development Positive Regulation Of Interleukin-6 Production Negative Regulation Of Heterotypic Cell-cell Adhesion Maintenance Of Blood-brain Barrier Myelination Membrane Organization Positive Regulation Of Metalloendopeptidase Activity Positive Regulation Of Chemokine (C-X-C Motif) Ligand 2 Production	MAPK Cascade Activation Of MAPK Activity Protein Phosphorylation Chemotaxis Cell Cycle Arrest Signal Transduction Heart Development Negative Regulation Of Cell Population Proliferation Positive Regulation Of Gene Expression Negative Regulation Of Gene Expression Peptidyl-threonine Phosphorylation Peptidyl-tyrosine Phosphorylation Cerebellar Cortex Formation Neuron Differentiation Keratinocyte Differentiation Thyroid Gland Development Regulation Of Stress-activated MAPK Cascade Positive Regulation Of Transcription, DNA-templated Thymus Development Regulation Of Axon Regeneration Cell Motility Positive Regulation Of Axonogenesis Bergmann Glial Cell Differentiation Face Development Trachea Formation Epithelial Cell Proliferation Involved In Lung Morphogenesis Placenta Blood Vessel Development Labyrinthine Layer Development ERK1 And ERK2 Cascade Positive Regulation Of ERK1 And ERK2 Cascade Positive Regulation Of Protein Serine/threonine Kinase Activity Regulation Of Golgi Inheritance Cellular Senescence Positive Regulation Of Production Of MiRNAs Involved In Gene Silencing By MiRNA Regulation Of Early Endosome To Late Endosome Transport
Pathways		EGR2 and SOX10-mediated initiation of Schwann cell myelination	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants
Drugs			K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide PD-0325901 N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib
Diseases			Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
GWAS		Age-related macular degeneration (geographic atrophy) ( 22705344) Blood osmolality (transformed sodium) ( 28360221) Depression in smokers ( 30219690) Erythrocyte cadmium concentration in never smokers ( 27005419) Paclitaxel disposition in epithelial ovarian cancer ( 29367611) Verbal declarative memory ( 25648963)	Prostate cancer ( 29892016) Testicular germ cell tumor ( 28604728 28604732)
Interacting Genes		81 interacting genes: ABL1 ADRB2 APTX ATN1 ATXN1 AURKA BMP2K CCR1 CDK1 CDK12 CDK5 CDK7 CDK8 CDK9 CLK1 CTDSP1 CTDSPL DYRK1B HIPK2 HLA-DRA IKBKE ILK IRAK1 IRAK4 LIMK1 LIMK2 LRRK2 MAG MAP2K1 MAP3K1 MAP3K3 MAP3K5 MAPK1 MAPK11 MAPK12 MAPK13 MAPK14 MAPK15 MAPK3 MAPK8 MAPKAPK5 MELK MICU2 MKNK1 MMP7 NEK9 PAK1 PDGFRL PKN1 PLEKHF2 PLP1 PPP2R5C PRKACA PRKCA PRKCB PRKCD PRKCI PRKCZ PRKDC PRMT1 PRMT5 PTAFR PTPRA RAF1 RAN RPS6KA5 RTN4 SQSTM1 SRPK1 STK16 STK26 STK3 STK39 STK4 TBK1 TLK1 TLK2 TRAF6 TRPM7 TSSK6 ULK1	67 interacting genes: APC ARAF AURKA BANP BAX BIRC6 BMPR1A BRAF BUB1 CASP9 CDH1 CDK5 CDKN2A CPNE1 CPNE4 CTNNA1 EGFR ELK1 EP300 ERBB2 FBXW7 GRB10 HNRNPD HRAS KAT7 KSR1 KSR2 LAMTOR3 MAP3K4 MAP3K8 MAPK1 MAPK14 MAPK3 MAPK8 MAPK8IP3 MBP MLH3 MSH6 MYC ODC1 PAK1 PARVA PDGFRL PEBP1 PEBP4 PIK3CA PLEKHF2 PLK3 PPARG PRKCI PRKCZ PTPRJ RAF1 RPS6KA2 RPS6KA4 SMAD2 SRC STK11 TCP11 TGFBR2 TLR2 TRAF3 TRAF6 TRIB1 UBE2I UBE2L3 WNK1
Entrez ID		4155	5604
HPRD ID		01158	01469
Ensembl ID		ENSG00000197971	ENSG00000169032
Uniprot IDs		A0A024R384 P02686	A4QPA9 B4DFY5 H3BRW9 Q02750
PDB IDs		1BX2 1FV1 1HQR 1K2D 1QCL 1YMM 1ZGL	1S9J 2P55 3DV3 3DY7 3E8N 3EQB 3EQC 3EQD 3EQF 3EQG 3EQH 3EQI 3MBL 3ORN 3OS3 3PP1 3SLS 3V01 3V04 3VVH 3W8Q 3WIG 3ZLS 3ZLW 3ZLX 3ZLY 3ZM4 4AN2 4AN3 4AN9 4ANB 4ARK 4LMN 4MNE 4U7Z 4U80 4U81 5BX0 5EYM 5HZE 5YT3 6NYB 6PP9 6Q0J 6Q0T 6U2G 6X2P 6X2S 6X2X
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?